Additional capacity enables MD Biosciences to increase the existing models as well as continue the development of new methods and biomarkers that help bridge the gap between nonclinical data and clinical outcomes.
MD Biosciences, a global preclinical contract research organization (CRO), announces the expansion of its preclinical contract research laboratory in St Paul, MN. The expansion of the laboratory provides additional capacity to increase the in vivo research models of its existing inflammations division. In addition to inflammations models, expansion into the areas of metabolic and cancer research are underway with metabolic studies already being offered. As part of this expansion, MD Biosciences is also hiring experienced scientists in these areas to join our St Paul research team.
As biopharma companies are dealing with reduced R&D budgets and pressures to replace revenue from patent expirations, bringing a clinical mindset to non-clinical study design assists in reducing late phase failures. MD Biosciences is continually developing new methods that help address the gap between non-clinical data and clinical outcomes. Often times existing preclinical models are all that is available but don’t necessarily reflect what is seen in the clinic – additional capacity enables MD Biosciences to continue its R&D program in search of new and more relevant preclinical models and biomarkers.
MD Biosciences currently offers a wide selection of in vivo models within inflammation/autoimmune, CNS, pain, wound healing and cardiovascular fields of research. Its focus is on the cross-talk between the immune and neural systems and the areas of overlap as well as contributions of one to the other in disease pathways. This deep understanding in the cross-talk and a strict focus on sponsors objectives enables MD Biosciences to contribute to the overall study design.
“The expansion of the preclinical contract research lab in the US assists us in serving both North American and International clients. Our global laboratories in the US, UK and Israel are positioned to be able to serve each market and research niche efficiently with strong scientific insight. Our approach to deeply understand each sponsors objectives allows us to contribute and invest scientifically in their program.” says CEO Eddie Moradian.
About MD Biosciences
MD Biosciences is a global preclinical contract research organization (CRO) specializing in the areas of autoimmune, CNS and cardiovascular. Our focus is not only on the science but also on the understanding of our clients’ objectives. This enables us to partner with our sponsors in the project design phase to ensure that studies accurately address the questions being asked. Research facilities are located in the US, UK and Israel – all strategically located within strong scientific and collaborative networks. The flexible, responsive and collaborative approach with a strong scientific understanding of systems cross-talk offers a unique offering to the biopharma community.
Forward looking statement:
The information in this press release should be considered accurate only as of the date of the release. MDB has no intention of updating and specifically disclaims any duty to update the information in these press releases.